• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BARD PERIPHERAL VASCULAR, INC. CROSSER CTO RECANALIZATION CATHETERS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BARD PERIPHERAL VASCULAR, INC. CROSSER CTO RECANALIZATION CATHETERS Back to Search Results
Catalog Number CRE14S
Device Problems Retraction Problem (1536); Detachment of Device or Device Component (2907)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Type  malfunction  
Manufacturer Narrative
The lot number for the device was provided; therefore, a lot history review is currently being performed.The device has been returned to the manufacturer for evaluation.The company is still investigating the issue at this time.The device is labeled for single use.The catalog number identified has not been cleared in the us, but is similar to the crosser cto recanalization catheter products that are cleared in the us.The pro code for the crosser cto recanalization catheter products is identified.
 
Event Description
This report summarizes one malfunction.A review of the reported information indicated that model cre14s recanalization catheter allegedly experienced retraction problem and detachment of device or device component.This information was received from one source.One patient was involved with no patient consequences.The age, weight, and gender of the patient was not provided.
 
Event Description
This report summarizes one malfunction.A review of the reported information indicated that model cre14s recanalization catheter allegedly experienced retraction problem and detachment of device or device component.This information was received from one source.One patient was involved with no patient consequences.The age, weight, and gender of the patient was not provided.
 
Manufacturer Narrative
H10: the lot number for the device was provided; therefore, a lot history review was performed.The device was not returned to the manufacturer for evaluation.The sample was not returned for evaluation; therefore, the investigation is inconclusive for the alleged issue.The root cause could not be determined based upon available information.It is unknown whether patient and/or procedural factors contributed to the event.The device is labeled for single use.H10: g4.H11: g1, h6 (result, conclusion).H10: the catalog number identified in section d4 has not been cleared in the us, but is similar to the crosser cto recanalization catheter products that are cleared in the us.The pro code for the crosser cto recanalization catheter products is identified in d2.H11: section a through f - the information provided by bd represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CROSSER CTO RECANALIZATION CATHETERS
Type of Device
RECANALIZATION CATHETER
Manufacturer (Section D)
BARD PERIPHERAL VASCULAR, INC.
1625 w 3rd st.
tempe AZ 85281
MDR Report Key9968925
MDR Text Key189219983
Report Number2020394-2020-02878
Device Sequence Number1
Product Code PDU
UDI-Device Identifier10801741125420
UDI-Public(01)10801741125420
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Type of Report Initial,Followup
Report Date 07/08/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator No Information
Device Catalogue NumberCRE14S
Device Lot NumberGFDU3094
Initial Date Manufacturer Received 03/31/2020
Initial Date FDA Received04/16/2020
Supplement Dates Manufacturer Received06/26/2020
Supplement Dates FDA Received07/08/2020
Patient Sequence Number1
-
-